Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Viewpoint - Esperion is focused on executing its current strategies while building for future growth, emphasizing its Vision 2040 initiative [2]. Company Overview - Esperion is currently commercializing two products: NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid plus ezetimibe) [3]. - The company is in a strong financial position, aiming for sustainable profitability by 2026, supported by durable cash flows and a robust balance sheet [3]. - Esperion has an attractive profit and loss profile, which is bolstered by its partnerships and product pipelines [3].